Evidence map›Paper›PMID 28866743›Full record

Trial reportEuropean journal of clinical pharmacology2017

Effects of oral Δ

Carmen Walter, Bruno G Oertel, Lisa Felden, Ulrike Nöth, Johannes Vermehren, Ralf Deichmann, Jörn Lötsch

Abstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in European journal of clinical pharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Carmen WalterFraunhofer Institute of Molecular Biology and Applied Ecology - Project Group Translational Medicine and Pharmacology (IME-TMP), Theodor - Stern - Kai 7, 60590, Frankfurt am Main, Germany.
Bruno G OertelInstitute of Clinical Pharmacology, Goethe - University, Theodor Stern Kai 7, 60590, Frankfurt am Main, Germany.
Lisa FeldenInstitute of Clinical Pharmacology, Goethe - University, Theodor Stern Kai 7, 60590, Frankfurt am Main, Germany.
Ulrike NöthBrain Imaging Center, Goethe - University, Schleusenweg 2 - 16, 60528, Frankfurt am Main, Germany.
Johannes VermehrenInstitute of Clinical Pharmacology, Goethe - University, Theodor Stern Kai 7, 60590, Frankfurt am Main, Germany.
Ralf DeichmannBrain Imaging Center, Goethe - University, Schleusenweg 2 - 16, 60528, Frankfurt am Main, Germany.
Jörn LötschFraunhofer Institute of Molecular Biology and Applied Ecology - Project Group Translational Medicine and Pharmacology (IME-TMP), Theodor - Stern - Kai 7, 60590, Frankfurt am Main, Germany. j.loetsch@em.uni-frankfurt.de.ORCID http://orcid.org/0000-0002-5818-6958
Goethe University Frankfurt · DEFraunhofer Institute for Translational Medicine and Pharmacology · DE

Funding

Bundesministerium für Bildung und Forschung DLR 01GO0203Deutsche Forschungsgemeinschaft DFG Lo 612/10-1
6 · The paper itself

Abstract

backgroundConsidering the increasing acknowledgment of the human sense of smell as a significant component of the quality of life, olfactory drug effects gain potential clinical importance. A recent observation in a human experimental context indicated that Δ

methodsEmploying a placebo-controlled randomized crossover design, an oral dose of 20 mg THC was administered in 15 healthy volunteers. The central processing of olfactory input, consisting of short pulses of gaseous vanillin or hydrogen sulfide, and for comparison, of non-odorous but painful carbon dioxide, were investigated before and after administration of THC or placebo in a pharmacological functional magnet resonance imaging study.

resultsFollowing THC administration, the vanillin stimuli lost their pleasantness and became hedonically inert. This observation had its functional correlate in reduced stimulus-associated brain activations located in the left amygdala, the hippocampus and superior temporal pole (peak MNI coordinates x = - 27, y = - 1, z = - 26 mm p = 0.039). Differences in amygdala activations were significantly correlated with the corresponding differences in vanillin pleasantness (p = 0.025). By contrast, no effects were observed on the perception of processing of H

conclusionsThe results support that THC induced a modulation of the central processing of olfactory input. The THC-induced reduction in the pleasantness of a pleasurable odor was accompanied by reduced activations in the limbic system. Results agree with previous observation of negative effects of cannabinoids on the human sense of smell and strengthen the evidence that THC-based medications will be among drugs with olfactory side effects.

Indexed as

Administration, OralAdultBrainCross-Over StudiesDronabinolHumansMagnetic Resonance ImagingPlacebosSmellYoung AdultDronabinolPlacebosCannabisHuman experimental studyHuman olfactionPharmacological functional magnet resonance immagingStatistical parametric mappingTranslational reseach

Identifiers

PMID28866743
OpenAlexW2753116928

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.